4th Quarter - Report

ALLIANCE FOR REGENERATIVE MEDICINE for ALLIANCE FOR REGENERATIVE MEDICINE

Firm
Client
Income
—
Expenses
$230,000
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Mikaela Naylon Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing. Newborn screening. FDA oversight.

LobbyistCovered position, as disclosed
JOHN AGUILAR New —

Contacted: Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH)

Bills named: S. 752 (119th), S. 891 (119th), S. 932 (119th), H.R. 1509 (119th), S. 1637 (119th), H.R. 1262 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.